- Home
- KUKE vs EPIX Comparison
KUKE vs EPIX Comparison
Compare KUKE & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- EPIX
- Stock Information
- Founded
- KUKE 2002
- EPIX 2009
- Country
- KUKE China
- EPIX Canada
- Employees
- KUKE N/A
- EPIX N/A
- Industry
- KUKE Other Consumer Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- EPIX Health Care
- Exchange
- KUKE Nasdaq
- EPIX Nasdaq
- Market Cap
- KUKE 86.8M
- EPIX 75.9M
- IPO Year
- KUKE 2021
- EPIX N/A
- Fundamental
- Price
- KUKE $1.95
- EPIX $0.23
- Analyst Decision
- KUKE
- EPIX Hold
- Analyst Count
- KUKE 0
- EPIX 3
- Target Price
- KUKE N/A
- EPIX $2.00
- AVG Volume (30 Days)
- KUKE 35.5K
- EPIX 14.6M
- Earning Date
- KUKE 10-15-2025
- EPIX 08-13-2025
- Dividend Yield
- KUKE N/A
- EPIX N/A
- EPS Growth
- KUKE N/A
- EPIX N/A
- EPS
- KUKE N/A
- EPIX N/A
- Revenue
- KUKE $9,442,397.00
- EPIX N/A
- Revenue This Year
- KUKE N/A
- EPIX N/A
- Revenue Next Year
- KUKE N/A
- EPIX N/A
- P/E Ratio
- KUKE N/A
- EPIX N/A
- Revenue Growth
- KUKE N/A
- EPIX N/A
- 52 Week Low
- KUKE $1.45
- EPIX $0.22
- 52 Week High
- KUKE $17.50
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- KUKE 50.01
- EPIX 5.65
- Support Level
- KUKE $1.60
- EPIX $0.23
- Resistance Level
- KUKE $1.99
- EPIX $0.26
- Average True Range (ATR)
- KUKE 0.11
- EPIX 0.02
- MACD
- KUKE 0.07
- EPIX -0.12
- Stochastic Oscillator
- KUKE 91.30
- EPIX 0.63
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.